The rejuvenated pressurised metered dose inhaler

Expert Opinion on Drug Delivery

Volumn 4, Issue 3, 2007, Pages 215-234

  Bell, John ^a   Newman, Steve ^b  

^a Stewart Erl Associates   (United Kingdom)

^b NONE

Author keywords

Breath actuated inhaler; Dry powder inhaler; Pressurised metered dose inhaler; Spacer device

Indexed keywords

ADRENALIN; ALCOHOL; AMILORIDE; ANTIOXIDANT; BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; CICLESONIDE; CROMOGLYCATE DISODIUM; CRYOFLUORANE; CYCLOSPORIN A; ERGOTAMINE; EVOHALER; FENOTEROL; FENTANYL; FLAVORING AGENT; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; ISOPRENALINE; LACTOSE; LEUPRORELIN; NEDOCROMIL SODIUM; OLEIC ACID; PHENYLEPHRINE; PHOSPHATIDYLCHOLINE; PIRBUTEROL; PIRBUTEROL ACETATE; SALBUTAMOL; SALBUTAMOL SULFATE; UNCLASSIFIED DRUG;

ASTHMA; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; FLOW RATE; HUMAN; INHALATION SPACER; INHALATIONAL DRUG ADMINISTRATION; INTERMETHOD COMPARISON; METERED DOSE INHALER; MIGRAINE; PLUME DISPERSION; POWDER INHALER; REVIEW;

AEROSOL PROPELLANTS; CHLOROFLUOROCARBONS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYDROCARBONS, FLUORINATED; METERED DOSE INHALERS; POWDERS;

EID: 34248639855     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.3.215     Document Type: Review

References (154)

1. ANDERSON PJ: History of aerosol therapy; liquid nebulization to MDIs and DPIs. Respir. Care (2005) 50:1139-1150.
2. SCIARRA JJ, STOLLER L: The science and technology of aerosol packaging. John Wiley, New York (1974).
3. THIEL CG: From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Respiratory Drug Delivery V. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press, Buffalo Grove (1996):115-123.
4. FINK JB: Metered dose inhalers, dry powder inhalers and transitions. Respir. Care (2000) 45:623-635.
5. BROWN BAS: Dispelling the myths of MDIs. Drug Delivery Technology (2002) 2:1-7.
6. TANSEY IP: The challenges in the development of metered-dose inhalation aerosols using ozone-friendly propellants. Proceedings of the First European Pharm. Tech. Conference, Dusseldorf (1993):182-187.
7. SMITH IJ, PARRY-BILLINGS M: The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. (2003) 16:79-95.
8. DALBY R, SPALLEK M, VOSHAAR T: A review of the development of Respimat soft mist inhaler. Int. J. Pharm. (2004) 283:1-9.
9. NOAKES T: Medical aerosol propellants. J. Fluorine Chem. (2002) 118:35-45.
10. SANDERS PA: Principles of aerosol technology. Van Nostrand Reinhold, New York (1970).
11. HALLWORTH GW: The formulation and evaluation of pressurised metered dose inhalers. In: Drug delivery to the respiratory tract. Ganderton D, Jones T (Eds). Ellis Horwood, Chichester (1987):87-118.
12. NEWMAN SP: Principles of metered-dose inhaler design. Respir. Care (2005) 50:1177-1190.
13. BYRON PR: Aerosol formulation, generation and delivery using metered systems. In: Respiratory Drug Delivery. Byron PR (Ed.). CRC Press, Boca Raton (1991):167-205.
14. BELL JH, BROWN K, GLASBY J: Variation in delivery of isoprenaline from various pressurized inhalers. J. Pharm. Pharmacol. (1973) 25(Suppl.):32P-36P.
15. CLARK AR: MDIs: physics of aerosol formation. J. Aerosol Med. (1996) 9(Suppl. 1):S19-S26.
16. DUNBAR CA, WATKINS AP, MILLER JF: Theoretical investigation of the spray from a pressurized metered-dose inhaler. Atomisation and Sprays (1997) 7:417-436.
17. VERSTEEG HK, HARGRAVE GK: Fundamentals and resilience of the original MDI actuator design. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):91-100.
18. RANCE RW: Studies of the factors controlling the action of hair sprays. J. Soc. Cosmet. Chem. (1974) 25:545-561.
19. GABRIO BJ, STEIN SW, VELASQUEZ DJ: A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int. J. Pharm. (1999) 186:3-12.
20. DOLOVICH M, RUFFIN RE, ROBERTS R, NEWHOUSE MT: Optimal delivery of aerosols from metered dose inhalers. Chest (1981) 80(Suppl.):911-915.
21. SHORT MD, SINGH CA, FEW JD, STUDDY PT, HEAF PJD, SPIRO SG: The labelling and monitoring of lung deposition of an inhaled synthetic anticholinergic bronchodilating agent. Chest (1981) 80(Suppl.):918-921.
22. NEWMAN SP, PAVIA D, GARLAND N, CLARKE SW: Effects of various inhalation modes on the deposition of radioactive pressurised aerosols. Eur. J. Respir. Dis. (1982) 63(Suppl. 119):57-65.
23. HINDLE M, NEWTON DAG, CHRYSTYN H: Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax (1993) 48:607-610.
24. NEWMAN SP: Scintigraphic assessment of therapeutic aerosols. Crit. Rev. Ther. Drug Carrier Syst. (1993) 10:65-109.
25. NEWMAN SP, WEISZ AWB, TALAEE N, CLARKE SW: Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax (1991) 46:712-716.
26. MOLINA MJ, ROWLANDS FS: Stratospheric sink for chlorofluoromethanes: chlorine atomcatalysed destruction of ozone. Nature (1974) 249:1810-1812.
27. PARTRIDGE MR, WOODCOCK AA, SHEFFER AL, WANNER A, RUBINFELD A: Chlorofluorocarbon-free inhalers: are we ready for the change? Eur. Respir. J. (1998) 11:1006-1008.
28. PARTRIDGE MR, WOODCOCK AA: Propellants. In: Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, Smaldone GC (Eds) Marcel Dekker, New York (2002):371-388.
29. LAWFORD P, MCKENZIE D: Pressurised aerosol inhaler technique: how important are inhalation from residual volume, inspiratory flow rate and time interval between puffs? Br. J. Dis. Chest (1983) 77:276-281.
30. NEWMAN SP, PAVIA D, CLARKE SW: How should a pressuriscd β-adrenergic bronchodilator be inhaled? Eur. J. Respir. Dis. (1981) 62:3-20.
31. RILEY DJ, LIU RT, EDELMAN NH: Enhanced responses to aerosolised bronchodilator therapy in asthma using respiratory maneuvers. Chest (1979) 76:501-507.
32. CROMPTON GK: Problems patients have using pressurised aerosol inhalers. Eur. J. Respir. Dis. (1982) 63(Suppl. 119):57-65.
33. MOLIMARD M, RAHERISON C, LIGNOT S, DEPONT F, ABOUELFATH A, MOORE N: Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol Med. (2003) 16:249-254.
34. LINDGREN S, BAKE B, LARSSON S: Clinical consequences of inadequate inhalation technique in asthma therapy. Eur. J. Respir. Dis. (1987) 70:93-98.
35. GIRAUD V, ROCHE N: Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur. Respir. J. (2002) 19:246-251.
36. BELL JH, HARTLEY PS, COX JSG: Dry powder aerosols I: a new powder inhalation device. J. Pharm. Sci. (1971) 10:1559-1564.
37. HALLWORTH GW: An improved design of powder inhaler. Br. J. Clin. Pharmacol. (1977) 4:689-690.
38. WETTERLIN K: Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm. Res. (1998) 5:506-508.
39. ASHURST I, MALTON A, PRIME D, SUMBY B: Latest advances in the development of dry powder inhalers. Pharm. Sci. Technol. Today (2000) 3:246-256.
40. BRINDLEY A, SUMBY BS, SMITH IJ, HAYWOOD PA, GRANT AC: Design, manufacture and dose consistency of the Serevent Diskus Inhaler. Pharm. Tech. Eur. (1995) 9:14-22.
41. LABIRIS NR, DOLOVICH MB: Pulmonary drug delivery. Part 1: physiological factors affecting therapeutic effectiveness of aerosolised medications. Br. J. Clin. Pharmacol. (2003) 56:588-599.
42. MORÉN F: Aerosol dosage forms and formulations. In: Aerosols in Medicine: principles, diagnosis and therapy. Morén F, Dolovich MB, Newhouse MT, Newman SP (Eds). Elsevier, Amsterdam (1993):321-350.
43. PEART J, CLARKE MJ: New developments in dry powder inhaler technology. Am. Pharm. Rev. (2001) October:27-45.
44. LABIRIS NR, DOLOVICH MB: Pulmonary drug delivery. Part 2: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolised medications. Br. J. Clin. Pharmacol. (2003) 56:600-612.
45. ATKINS PJ: Dry powder inhalers: an overview. Respir. Care (2005) 50:1304-1312.
46. TOBYN M, STANIFORTH JN, MORTON D, HARMER Q, NEVTrON ME: Active and intelligent inhaler device development. Int. J. Pharm. (2004) 277:31-37.
47. FINK JB, RUBIN BK: Problems with inhaler use: a call for improved clinician and patient education. Respir. Care (2005) 50:1360-1375.
48. PRICE D: The way forward: dry powder inhalers should only be switched with physician agreement and patient training. Int. J. Clin. Pract. (2005) 59(Suppl. 59):36.
49. KELLING JS, STROHL KP, SMITH RL, ALTOSE MD: Physician knowledge in the use of canister nebulisers. Chest (1983) 83:612-614.
50. KESTEN S, ZIVE K, CHAPMAN KR: Pharmacist knowledge and ability to use inhaled medication delivery systems. Chest (1993) 104:1737-1742.
51. RAU JL: Determinants of patient adherence to an aerosol regimen. Respir. Care (2005) 50:1346-1359.
52. LEACH CL: The CFC to HFA transition and its impact on pulmonary drug development. Respir. Care (2005) 50:1201-1208.
53. ATKINS PJ: Transition to HFA MDIs: how did we get there and where are we going? In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):83-90.
54. SMITH IJ: The challenge of reformulation. J. Aerosol Med. (1995) 8:S19-S27.
55. VERVAET C, BYRON PR: Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm. (1999) 186:13-20.
56. CROWDER TM, LOUEY MD, SETHURAMAN VV, SMYTH HD, HICKEY AJ: 2001: An odyssey in inhaler formulation and design. Pharm. Tech. (2001) July:100-113.
57. STEFELY JS, DUAN DC, MYRDAL PB, ROSS DL, SCHULTZ DW, LEACH CL: Design and utility of a novel class of biocompatible excipients for HFA-based MDIs. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds). Serentec Press, Raleigh (2000):83-90.
58. STEFELY JS, BROWN B, HAMMERBECK DM, STEIN SW: Equipping the MDI for the 21st century by expanding its formulation options. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood, Raleigh (2002):207-214.
59. CRIPPS A, RIEBE M, SCHULZE M, WOODHOUSE R: Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir. Med. (2000) 94(Suppl. B):S3-S9.
60. PEYRON ID, BRITTO IL, BENISSAN LB, TARDIEU BZ: Development and performance of a new hydrofluoroalkane (HFA-134a) based metered dose inhaler of salbutamol. Respir. Med. (2005) 99(Suppl. A):S20-S30.
61. LEACH CL, DAVIDSON PJ, HASSELQUIST BE, BOUDREAU RJ: Lung deposition of hydrofluroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest (2002) 122:510-516.
62. GANDERTON D, LEWIS D, DAVIES R, MEAKIN B, BRAMBILLA G, CHURCH T: Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir. Med. (2002) 96(Suppl. D):S3-S8.
63. SMYTH HDC: The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Advanced Drug Delivery Revs. (2003) 55:807-828.
64. SMYTH H, BRACE G, BARBOUR T, GALLION J, GROVE J, HICKEY AJ: Spray pattern analysis for metered dose inhalers: effect of actuator design. Pharm. Res. (2006) 23:1591-1596.
65. LEWIS DA, GANDERTON D, MEAKIN BJ, BRAMBILLA G: Theory and practice with solution systems. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2004):109-115.
66. WOODCOCK A, ACERBI D, POLI G: Modulite technology: pharmacodynamic and pharmacokinetic implications. Respir. Med. (2002) 96(Suppl. D):S9-S15.
67. LEWIS DA, MEAKIN BJ, BRAMBILLA G: New actuators versus old: reasons and results for actuator modifications for HFA solution MDIs. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):101-110.
68. POLLI GP, GRIM WM, BACHER FA, YUNKER MH: Influence of formulation on aerosol particle size. J. Pharm. Sci. (1969) 58:484-486.
69. FOOD AND DRUG ADMINISTRATION: Chlorofluorocarbon propellants in self-propelled containers; addition to list of essential uses. Federal Register (1993) 58:6086-6088.
70. COLTHORPE P: Industry experiences of the HFA transition. Drug Delivery Systems and Sciences (2003) 3:41-43.
71. HOCHRAINER D, HÖLZ H, KREHER C, SCAFFIDI L, SPALLEK M, WACHTEL H: Comparison of the aerosol velocity and spray duration of Respimat soft mist inhaler and pressurized metered dose inhaler. J. Aerosol Med. (2005) 18:273-282.
72. ASHWORTH HL, WILSON CG, SIMS EE, WOTTON PK, HARDY JG: Delivery of propellant soluble drug from a metered dose inhaler. Thorax (1991) 46:245-247.
73. LEACH CL, DAVIDSON PJ, BOUDREAU RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. (1998) 12:1346-1353.
74. BUSSE WW, BRAZINSKY S, JACOBSON K et al.: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. (1999) 104:1215-1222.
75. DEROM E, PAUWELS RA: Pharmacokinetic and pharmacodynamic properties of inhaled beclomethasone dipropionate delivered via hydrofluoroalkane-containing devices. Clin. Pharmacokinet. (2005) 44:815-836.
76. HARRISON LI: Local versus total systemic bioavailability of beclomethasone dipropionate CFC and HEA metered dose inhaler formulations. J. Aerosol Med. (2002) 15:401-406.
77. TASHKIN DP: HFA-BDP and its implications for the quiet zone. Respir. Med. (2000) 94(Suppl. D):S37-S39.
78. NEWMAN SP, PITCAIRN GR, KALIRAI CS et al.: Using gamma scintigraphy and single photon emission computed tomography to assess the pulmonary deposition of a new inhaled formulation of flunisolide. In: Drug Delivery to the Lungs XIII. The Aerosol Society, Portishead (2002):87-90.
79. LEACH CT, BETHKE TD, BOUDREAU RJ et al.: Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a non-randmized study in healthy volunteers. J. Aerosol Med. (2006) 19:117-126.
80. DEVADASON SG, HUANG T, WALKER S, TROEDSON R, LE SOUEF PN: Distribution of technetium-99m-labelled QVAR delivered using an Aurohaler device in children. Eur. Respir. J. (2003) 21:1007-1011.
81. BORGSTRÖM L OLSSON B, THORSSON L: Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J. Aerosol Med. (2006) 19:473-483.
82. CYR TD, GRAHAM SJ, LI KYR, LOVERING EG: Low first-spray drug content in albuterol metered-dose inhalers. Pharm. Res. (1991) 8:658-660.
83. TOPLISS P, WARD D, SOUTHALL J, PUREWAL T: Pharmaceutical performance of a valve for metered dose inhalers designed to eliminate loss of prime. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):499-502.
84. ROSS DL, GABRIO BJ: Advances in metered dose inhaler technology with the development of a chloroflurocarbon-free drug delivery system. J. Aerosol Med. (1999) 12:151-160.
85. MARTIN AR, KWOK DY, FINLAY WH: Investigating the evaporation of metered-dose inhaler formulations in humid air: single droplet experiments. J. Aerosol Med. (2005) 18:218-224.
86. NEWMAN SP: Inhaler treatment options in COPD. European Respiratory Review (2005) 14:102-108.
87. HINDLE M, BYRON PR: Dose emissions from marketed dry powder inhalers. Int. J. Pharm. (1995) 116:169-177.
88. PRITCHARD JN: The future of metered-dose inhalers. Pharm. Tech. Eur. (2005) September:22-31.
89. MEAKIN BJ, STROUD N: An evaluation of some metered dose aerosols using a twin stage impinger sampling device. J. Pharm. Pharmacol. (1983) 35(Suppl. 10):7P.
90. STEIN SW, FORSYTH BR, STEFELY JS, CHRISTENSEN JD, ALBAND TD, JINKS PA: Expanding the dosing range of metered dose inhalers through formulation and hardware optimisation. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2004):125-133.
91. RUBIN BK, DUROTOYE L: How do patients determine that their metered-dose inhaler is empty? Chest (2004) 126:1134-1137.
92. SANDER N, FUSCO-WALKERT SJ, HARDER JM, CHIPPS BE. Dose counting and the use of pressurized metered-dose inhalers: running on empty. Ann. Allergy Asthma Immunol. (2006) 97:34-38.
93. CAIN WT, OPPENHEIMER JJ: The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. Ann. Asthma Allergy Immunol. (2001) 87:417-419.
94. FOOD AND DRUG ADMINISTRATION: Guidance for industry: integration of dose counting mechanisms into MDI drug products (2003).
95. EUROPOEAN AGENCY FOR EVALUATION OF MEDICINAL PRODUCTS: Final guideline on the quality of inhalation and nasal products (2005).
96. BRADSHAW DRS: Developing dose counters: an appraisal based on regulator, pharma and user needs. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):121-131.
97. HALLEY M: A review of the design and the development of GSK's MDI dose counter. In: Drug Delivery to the Lungs 16. The Aerosol Society, Portishead (2005):77-80.
98. SHETH K, WASSERNAN RL, LINCOURT WR, LOCANTORE NW, CARRANZA-ROSENZWEIG J, CRIM C: Fluticasone propionate/salmeterol hydrofluoroalkane via metered dose inhaler with integrated dose counter: performance and patient satisfaction. Int. J. Clin. Pract. (2006) 60:1218-1224.
99. CHRISTENSEN A, DEVINE T: Can patient adherence be improved with technology? In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):479-481.
100. INGRAM S, NEWELL H, NINAN S, SOUTHWELL J, WARBY R: Design, development and analysis of an integrated pMDI dose counter. In: Drug Delivery to the Lungs 16. The Aerosol Society, Portishead (2005):148-151.
101. MAHON G, PURKINS G: Selecting a dose counter for pMDIs. In: Respiratory Drug Delivery Europe. Dalby RN, Byron PR, Peart J, Suman JD (Eds), Davis Healthcare International, River Grove, Illinois (2005):165-167.
102. BAUM EA: Design, development and testing of a new breath actuated inhaler. In: Inspiration: Developments in inhalation therapy. The Medicine Publishing Foundation, Oxford (1989):21-30.
103. HARDY JG, JASUJA AK, FRIER M, PERKINS AC: A small volume spacer for use with a breath-operated pressurised metered dose inhaler. Int. J. Pharm. (1996) 142:129-133.
104. FARR SJ, ROWE AM, RUBSAMEN R, TAYLOR G: Aerosol deposition in the human lung following administration from a microprocessor controlled metered dose inhaler. Thorax (1995) 60:639-644.
105. BACON RJ, MCDERMOTT I, BELL J: A new breath operated actuator. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood, Raleigh (2002):403-406.
106. MOHSEN N: pMDI aerosol momentum manipulation and biotargeted delivery. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood, Raleigh (2002):593-597.
107. HUSEGAARD C: Consumer electronics to medical devices: a cross-industry perpective on technology development: breathing new life into next generation inhalers, a consumer-inspired next generation pMDI. In: Drug Delivery to the Lungs 17. The Aerosol Society, Portishead (2006):54-58.
108. PRICE D, THOMAS M, MITCHELL G, NIZIOL C, FEATHERSTONE R: Improvement of asthma control with a breath-actuated pressurized metered dose inhaler: a prescribing claim study of 5556 patients using a traditional pressurized metered dose inhaler or a breath-actuated device. Respir. Med. (2003) 97:12-19.
109. BYRON PR: Platform selection for inhaled drugs: biological and regulatory merit of different approaches. In: Respiratory Drug Delivery Europe. Dalby RN, Byron PR, Peart J, Suman JD (Eds). Davis Healthcare International, River Grove, Illinois (2005):1-17.
110. CHAPMAN KR, LOVE L, BRUBAKER H: A comparison of breath-actuated and conventional metered dose inhaler inhalation techniques in elderly subjects. Chest (1993) 104:1332-1337.
111. LENNEY J, INNES JA, CROMPTON GK: Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir. Med. (2000) 94:496-500.
112. PEDERSEN S, MORTENSEN S: Use of different inhalation devices in children. Lung (1990) 168(Suppl.):653-657.
113. PEDERSEN S: Choice of inhalation therapy in paediatrics. Eur. Respir. J. (1994) 18:85-88.
114. CROMPTON GK: Breath-activated aerosol. Br. Med. J. (1971) 2:652-653.
115. CROMPTON GK: The adult patient difficulties with inhalers. Lung (1990) 168(Suppl.):658-662.
116. LEACH CL, DAVIDSON PJ, HASSELQUIST BE, BOUDREAU RJ: Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J. Aerosol Med. (2005) 18:379-385.
117. CHAPMAN KR, VOSHAAR TH, VIRCHOW JC. Inhaler choice in primary practice. European Respiratory Review (2005) 14:117-122.
118. DALBY R, ZIEGLER L, SOMARAJU S, TSOUKLERIS M, TEETER J: The effect of time delays between inhaler actuation and onset of inhalation on the dose of albuterol exiting Optihaler, Aerochamber and Aerosol Cloud Enhancer spacers. In: Respiratory Drug Delivery V. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press, Buffalo Grove (1996):324-326.
119. HOWLETT D: Devices to assist patient co-ordination with pMDIs: a review. In: Drug Delivery to the Lungs IX. The Aerosol Society, Portishead (1998):184-187.
120. ZHANG FL, GENOVA PA, TANGUAY JF et al.: The breath coordinated inhaler (BCI): a new pulmonary drug delivery device for pressurized metered dose inhalers. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds). Serentec Press, Raleigh (2000):323-326.
121. O'CALLAGHAN C, WRIGHT P: The metered-dose inhaler. In: Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, Smaldone GC (Eds). Marcel Dekker, New York (2002):337-370.
122. NEWMAN SP, STEED KP, HOOPER G, JONES JI, UPCHURCH FC: Improved targeting of beclomethasone dipropionate (250 μg metered dose inhaler) to the lungs of asthmatics with the Spacehaler. Respir. Med. (1999) 93:424-431.
123. NEWNHAM DM, MCDEVITT DG, LIPWORTH BJ: Comparison of the extrapulmonary β-2 adrenoceptor responses and pharmacokinetics of salbutamol metered dose-inhaler and modified actuator device. Br. J. Clin. Pharmacol. (1993) 36:445-450.
124. NEWMAN SP, CLARKE SW: Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest(1993) 103:1442-1446.
125. NEWMAN SP, HIRST PH, BACON RE et al.: Pulmonary delivery of ergotamine tartrate using a new breath-actuated pressurized aerosol device, the aerosol drug delivery system. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds). Serentec Press, Raleigh (2000):471-473.
126. KAKADE P, VERSTEEG H, DEATON D, HARGRAVE G: Design optimization of a novel MDI actuator. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):663-666.
127. NEWMAN SP, NEWHOUSE MT: Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J. Aerosol Med. (1996) 9:55-70.
128. TOBIN MJ, JENOURI G, DANTA I, KIM C, WATSON H, SACKNER MS: Response to bronchodilator drug administration by a new reservoir aerosol delivery system and a review of other auxiliary delivery systems. Am. Rev. Respir. Dis. (1982) 126:670-765.
129. SCHEUCH G, KOLB T, SOMMERER K, ROEDER S: In vitro evaluation of the novel spacer device Watchhaler and modeling of probable deposition in children. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):385-387.
130. NEWMAN SP: Spacer devices for metered dose inhalers. Clin. Pharmacokinet. (2004) 43:349-360.
131. BISGAARD H, ANHOJ J, WILDHABER JH: Spacer devices. In: Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, Smaldone GC (Eds). Marcel Dekker, New York (2002):389-420.
132. GLEESON JGA, PRICE JF: Nebuhaler technique. Br. J. Dis. Chest (1988) 82:172-174.
133. O'CALLAGHAN C, LYNCH J, CANT M, ROBERTSON C: Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation and avoiding multiple actuations of drug. Thorax (1993) 48:603-606.
134. BARRY PW, O'CALLAGHAN C: The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br. J. Clin. Pharmacol. (1995) 40:76-78.
135. MITCHELL J, MORTON R, SCHMIDT J, SNYDER S, DOYLE C, NAGEL M: Overcoming electrostatic charge retention in a new valved holding chamber (VEC): in vitro performance comparison with current devices. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2004):705-707.
136. RUBIN BK, FINK JB: Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir. Care (2005) 50:1191-1200.
137. BRAND PLP, ROORDA RJ: Drug delivery in pediatric patients with asthma spacer devices versus nebulizers for β-2 agonlists. Am. J. Drug Deliv. (2003) 1:61-70.
138. GELLER DE: Comparing clinical features of the nebulizer, metered dose inhaler and dry powder inhaler. Respir. Care (2005) 50:1313-1322.
139. ATKINS P: Discussion following NEWMAN SP: Principles of metered-dose inhaler design. Respir. Care (2005) 50:1177-1190.
140. SMYTH HD; Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin. Drug Delivery (2005) 2:53-74.
141. BOUNDY MG, LEITH D, KNOWLES MR: Dispersion and size distribution of amiloride by metered dose and dry powder inhalers. J. Aerosol Med. (1990) 3:233-241.
142. MATHER LE, WOODHOUSE A, WARD ME, FARR SJ, RUBSAMEN RA, ELTHERINGTON LG: Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br. J. Clin. Pharmacol. (1998) 46:37-43.
143. ADJEI A, SUNDBERG D, MILLER J, CHUN A: Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res. (1992) 9:244-249.
144. BROWN AR: Propellant-driven aerosols of proteins. Aerosol Science and Technology (1996) 24:45-56.
145. MARAJANI R, SHAIK MS, CHATTERJEE A, SINGH M: Evaluation of metered dose inhaler (MDI) formulations of ciclosporin. J. Pharm. Pharmacol (2007) 59:15-21.
146. BROWN AR, CHOWDHURY SL: Propellant-driven aerosols of DNA plasmids for gene expression in the respiratory tract. J. Aerosol Med. (1997) 10:129-146.
147. BARNES PJ: The problem of cough and development of novel and-tussives. Pulm. Pharmacol. Ther. (2006) Epub ahead of print.
148. PRITCHARD JN, GENOVA P: Adapting the pMDI to deliver novel drugs: insulin and beyond. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):133-141.
149. FRADLEY G: The pMDI - celebrating a golden history, welcoming a bright future. In: Drug Delivery to the Lungs 17. The Aerosol Society, Portishead (2006):38-41.
150. CROMPTON GK, BARNES PJ, BROEDERS M et al.: The need to improve inhalation technique in Europe: a report from the aerosol drug management improvement team. Respir. Med. (2006) 27:1070-1071.
151. COCHRANE MG, BALA MV, DOWNS KE, MAUSKOPF J, BEN-JOSEPH RH: Inhaled corticosteroids for asthma therapy: patient compliance, devices and inhalation technique. Chest (2000) 117:542-550.
152. DOLOVICH MB, AHRENS RC, HESS DR et al.: Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest (2005) 127:335-371.
153. LEWIS D, BRAMBILLA G, CHURCH T, MEAKIN B: BDP and formoterol association within combination HFA solution MDI. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):939-942.
154. DHILLON S, KEATING GM: Beclomethasone dipropionate/formoterol: In an HFA-propelled pressurised metered dose inhaler. Drugs (2006) 66:1475-1483.